Synergy Pharma's bowel drug succeeds in key study

Synergy Pharmaceuticals Inc said its experimental oral drug, plecanatide, met the main goal of a late-stage study on irritable bowel syndrome patients with constipation (IBS-C), according to an analysis of preliminary data.Reuters | Updated: December 10, 2016, 08:01 IST

Both doses of the drug outperformed a placebo in patients who were overall responders, or those whose abdominal pain was reduced by 30 percent or more and whose spontaneous bowel movements increased at least once in the same week, for at least half of the 12 treatment weeks, Synergy Pharma said.

The company's stock was halted in premarket trading. (Reporting by Natalie Grover in Bengaluru; Editing by Savio D'Souza)

This Website Uses Cookies

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you've provided to them or that they've collected from your use of their services. Give your consent to our cookies for: